July, 2015
Medtown Ventures forms a new company, CellectCell Inc., to focus on commercialization of adhesive-signature based cell selection technology invented by the McDevitt and Garcia labs.
Read Article


Medtown Ventures, LLC (“Medtown”), a venture development firm that specializes in the capitalization and commercialization of promising life science companies today announced that it has entered into an exclusive license agreement with Georgia Tech Research Corporation for a new adhesive-signature based stem cell selection and isolation technology. To focus on the commercialization of this new cell selection and isolation technology, Medtown has formed a new company, CellectCell™ Inc., with the inventors of the technology. The signed license agreement allows CellectCell, Inc. to develop manufacture, use and sell products containing the technology for all fields of use.

“We have been using this technology in our own research and believe it will revolutionize the ease and specificity with which specific cell types can be isolated for research” stated Andrés García Ph.D., Rae S. and Frank H. Neely Chair and Regents’ Professor, Woodruff School of Mechanical Engineering, Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, one of the inventors at Georgia Tech and a co-founder of CellectCell. “We are excited to work with a company like Medtown who provides the expertise needed to push a new technology like this to commercial success.”

“The μSHEAR™ technology developed by the McDevitt and Garcia labs will allow for researchers to isolate populations of cells with greater than 95% purity in less than 5 minutes while not altering or manipulating the cell itself.

"We believe this is game changing technology for both research based activities as well as product development,” stated Chris Fair, Founder and Managing Partner of Medtown.

“Highly efficient and scalable methods to isolate stem cells and their progeny in a label-free manner are virtually non-existent currently in laboratory cell culture practices and manufacturing pipelines,” stated Todd McDevitt Ph.D., also a co-inventor and co-founder of CellectCell, and formerly Carol Ann and David D. Flanagan Professor of Biomedical Engineering at Georgia Tech and Director of the Stem Cell Engineering Center at Georgia Tech. McDevitt is now a Senior Investigator at the Gladstone Institutes and Professor in the Department of Bioengineering & Therapeutic Sciences at UCSF in San Francisco, CA. “These unique characteristics of the μSHEAR technology make it a truly novel and disruptive technology for the entire stem cell industry.”

Ongoing research is being conducted on various types of stem cells with therapeutic promise for a variety of diseases. There are more than 300 labs in the US performing stem cell research activities, more than 40 universities with stem-cell based graduate programs, and multiple state programs providing funding and support for stem cell research.

The CellectCell technology will be presented at the Business of Regenerative Medicine: Cells at Work Conference on Wednesday, July 22nd in Atlanta, Georgia.

Any questions or comments can be directed to Rebecca Marshall, President, CellectCell, Inc. at Rebecca@medtownventures.com.


About Medtown Ventures

Medtown Ventures is a commercialization and venture firm that focuses on life science, medical device and biologic technologies. Our experienced team identifies and executes on strategic opportunities that enhance the value of our client companies, which in turn mitigates investor risk and ensures maximum financial return to all stakeholders.


Related Articles

Medtown Ventures, LLC Announces Exclusive License Agreement With Georgia Tech Research Corporation

Adhesive Differences Enable Separation of Stem Cells to Advance Potential Therapies